Osteoporosis in patients with inflammatory bowel disease: risk factors, prevention, and treatment.
Patients with inflammatory bowel disease (IBD) are at increased risk for osteoporotic fracture. Bone density testing and osteoporosis management are recommended for IBD patients at greater risk for fracture (ie, postmenopausal women, men aged . 60 years, and those with low body mass indices, glucocorticoid use, family history of osteoporosis, and malabsorption). Patient management includes modification of osteoporosis risk factors, such as calcium and vitamin D supplementation, hormone deficiency correction, and smoking cessation. When indicated, bisphosphonates, such as risedronate and alendronate, have been shown to increase bone mass and reduce fracture risk in patients with glucocorticoid-induced osteoporosis. Infliximab, an anti-tumor necrosis factor a antibody, increases bone mineral density, but this effect has not as yet translated into reduced fracture risk.
Katz
Seymour
S
New York University School of Medicine, New York, NY, USA.
D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D005938:Glucocorticoids / Q000009:adverse effects; D020249:Hormone Replacement Therapy; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000150:complications* / Q000188:drug therapy; D010024:Osteoporosis / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control* / Q000628:therapy*; D012307:Risk Factors
D050071:Bone Density Conservation Agents; D005938:Glucocorticoids